Get started
Author

Irene S. DeGutis

Observed names: DeGutis, Irene, I. DeGutis, I. S. DeGutis, Irene DeGutis, Irene Degutis, Irene S. Degutis
ORCID: 0000-0003-3190-5227
Observed ORCID: 0000-0003-3190-5227
OpenAlex ID: A5077880353
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
2018 · Rüdiger Hehlmann, Jorge E. Cortes, et al. · American Journal of Hematology · 57
PDF
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
2023 · John Mascarenhas, Claire Harrison, et al. · Clinical Lymphoma Myeloma & Leukemia · 16
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
2023 · Benjamin Tomlinson, Marcos de Lima, et al. · Transplantation and Cellular Therapy · 14
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study – SIMPLICITY
2025 · Michael J. Mauro, Rüdiger Hehlmann, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 7
PDF
Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry
2021 · Rami S. Komrokji, Tracy I. George, et al. · Blood · 4
Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial
2019 · Massimo Breccia, Jorge E. Cortes, et al. · Blood · 4
Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study
2023 · David L. Grinblatt, Gail J. Roboz, et al. · Blood · 3
PDF
Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.
2023 · Javid J. Moslehi, Mandar A. Aras, et al. · Journal of Clinical Oncology · 3
PDF
Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study
2020 · Michael J. Mauro, Vivian G. Oehler, et al. · Blood · 3
MPN-070 Real-World Clinical Outcomes in Patients With Myelofibrosis (MF) Previously Treated With Ruxolitinib (RUX)
2023 · Tania Jain, Harvey Katzen, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
2022 · John Mascarenhas, Claire Harrison, et al. · Blood · 2
The Use of Fedratinib (FEDR) for Myelofibrosis (MF) As a Potential Bridge to Hematopoietic Stem Cell Transplantation (HSCT) after Ruxolitinib (RUX) Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptoms, and Hematologic Response
2024 · John Mascarenhas, Claire Harrison, et al. · Transplantation and Cellular Therapy · 1
Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
2022 · Michael Mauro, Ronald Paquette, et al. · Blood · 1
Treatment Patterns and Survival Outcomes of Patients with Acute Myeloid Leukemia Who Achieved Remission in the Connect ® Myeloid Disease Registry
2021 · Gail J. Roboz, Mehrdad Abedi, et al. · Blood · 1
Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION
2020 · Massimo Breccia, Michael J. Mauro, et al. · Blood · 1
CML-023: Relationship Between High Body Mass Index (BMI) and Treatment Outcomes in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Dasatinib or Imatinib: Retrospective Analysis of the Phase 3 DASISION Trial
2020 · Massimo Breccia, Jorge E. Cortes, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Treatment utilization and outcomes in patients with mycosis fungoides and Sézary syndrome receiving mogamulizumab in community and academic practice in the United States clinical practice
2026 · B. M. Haverkos, C. Chang, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Real-world monotherapy and combination usage of mogamulizumab among patients with mycosis fungoides or Sézary syndrome in the United States
2025 · Bradley Haverkos, Chunlan Chang, et al. · Blood
POSTER: AML-547 Prognostic Effect of Co-Mutations on Patients With NPM1+ Acute Myeloid Leukemia (AML) Enrolled in the Connect® Myeloid Registry
2023 · Jaroslaw Maciejewski, Daniel Pollyea, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-070 Real-World Clinical Outcomes in Patients With Myelofibrosis (MF) Previously Treated With Ruxolitinib (RUX)
2023 · Tania Jain, Harvey Katzen, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-547 Prognostic Effect of Co-Mutations on Patients With NPM1+ Acute Myeloid Leukemia (AML) Enrolled in the Connect® Myeloid Registry
2023 · Jaroslaw Maciejewski, Daniel Pollyea, et al. · Clinical Lymphoma Myeloma & Leukemia
P589: Implications of Registry Data for Acute Myeloid Leukemia (aml) Treatment and Care During the Covid-19 Pandemic
2023 · Bart Scott, Mikkael Sekeres, et al. · HemaSphere
P1059: Real-world Treatment Patterns and Healthcare Resource Utilization in Myelofibrosis Patients With Anemia
2023 · John Mascarenhas, Krishnaveni Subbiah, et al. · HemaSphere
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories
2023 · Jay L. Patel, Harry P. Erba, et al. · Journal of Molecular Diagnostics
PDF
Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study.
2023 · Bart L. Scott, Mikkael A. Sekeres, et al. · Journal of Clinical Oncology
Works count: 40
Citation count: 120
H-index: 4
I10-index: 3
Year
Topic
Type